Sage Therapeutics. has been granted a patent for neuroactive steroids that act as GABA modulators, potentially useful for inducing sedation and anesthesia. The patent includes specific compounds and their pharmaceutical compositions, as well as methods for their application in treatment. GlobalData’s report on Sage Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sage Therapeutics, Anti-inflammatory anesthetics was a key innovation area identified from patents. Sage Therapeutics's grant share as of July 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12071453B2 encompasses a series of claims related to specific chemical compounds, particularly those represented by Formula (Ib) and its derivatives. The claims detail various structural configurations of these compounds, including the presence of substituents such as cyano, halo, and alkyl groups, as well as specific functional groups like —C(O)Ra and —S(O)0-2Ra. The patent also specifies conditions under which these compounds can exist, such as the values of 'n' and the nature of substituents R1, R2, and R4. Notably, the compounds may include benzotriazole and its derivatives, as well as other heteroaryl structures, indicating a focus on complex organic molecules with potential pharmaceutical applications.
In addition to the structural claims, the patent outlines a pharmaceutical composition that includes these compounds or their pharmaceutically acceptable salts, combined with suitable excipients. Furthermore, it describes methods for therapeutically treating various conditions, including depression, insomnia, seizures, and anxiety disorders, by administering these compounds in effective amounts. The administration routes specified include oral and intramuscular methods, highlighting the versatility of the compounds in clinical applications. Overall, the patent presents a comprehensive framework for the development of novel therapeutic agents based on the specified chemical structures.
To know more about GlobalData’s detailed insights on Sage Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
